In light of the COVID-19 pandemic, unanticipated supply chain disruptions and postponed FDA inspections have created significant risks and challenges for the global medical product manufacturing network. The recently enacted CARES Act and new FDA guidance have established a new framework for addressing supply chain disruptions through formal risk management plans. In this webinar, presenters will discuss regulatory requirements as well as strategies for developing a post-Coronavirus recovery action plan, how to implement and manage an effective plan, and how to be prepared for an establishment inspection, whether through record reviews or during on-site inspections post-crisis.
- +$150 for nonmembers
Internet Explorer and Microsoft Edge are not supported by the checkout process.
Please use Chrome, Firefox, or Safari. If you are unable to use these browsers, please contact us at 202-371-1420 or [email protected] and we will assist you.
Daniel Barreto, President and CEO, PharmQ Global Consulting
Cathy L. Burgess, Partner, Alston & Bird LLP and Member, FDLI Board of Directors
Joseph Jimenez, Managing Director, Arches Consulting, LLC
Moderated by Robert A. Rhoades, Managing Partner, Validant
Virtual Learning FAQ